Here are five other takeaways from the preliminary financial report:
- Fourth-quarter revenue, excluding COVID-19 testing, grew 28 percent compared to the same period last year.
- Including COVID-19 testing, revenue increased by 16 percent.
- COVID-19 testing revenue decreased by 87 percent with a reported $5.9 million in revenue.
- Screening revenue increased by 41 percent with an estimated revenue between $401.8 and $402.8 million, excluding the PreventionGenetics acquisition.
- Including the PreventionGenetics acquisition, screening revenue was up by 45 percent.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
